Oblique Therapeutics is a curiosity-driven, innovative biotech company with strong scientific acumen and drive for increasing the bandwidth of antibody therapeutics for the benefit of patients.

We have a solid portfolio of promising future medicines and proprietary AbiprotTM technology, our evergreen antibody platform that can generate functional antibodies to any given disease-modifying target.

We are focusing on finding new treatment paradigms for severe diseases such as advanced cancer and pain. We also work on two type 2 diabetes programs through a major pharma collaboration.

Recent news

28 mar 2019

We welcome our new owners

We would like to welcome our new international- as well as Scandinavian owners after closing this funding round.

07 mar 2019

New collaboration with Pharma

Oblique Therapeutics has entered into a collaboration agreement with a mid-sized Pharma for the development of the TRPV1…